EA201100132A1 - Единичная доза ападеносона - Google Patents

Единичная доза ападеносона

Info

Publication number
EA201100132A1
EA201100132A1 EA201100132A EA201100132A EA201100132A1 EA 201100132 A1 EA201100132 A1 EA 201100132A1 EA 201100132 A EA201100132 A EA 201100132A EA 201100132 A EA201100132 A EA 201100132A EA 201100132 A1 EA201100132 A1 EA 201100132A1
Authority
EA
Eurasian Patent Office
Prior art keywords
single dose
apadenoson
pharmacological
agent
apadenosone
Prior art date
Application number
EA201100132A
Other languages
English (en)
Other versions
EA022348B1 (ru
Inventor
Роберт Хендел
Уильям Б. Стиллей
Шэннон П. Уильямс
Original Assignee
Юниверсити Оф Вирджиния Пэтент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Вирджиния Пэтент Фаундейшн filed Critical Юниверсити Оф Вирджиния Пэтент Фаундейшн
Publication of EA201100132A1 publication Critical patent/EA201100132A1/ru
Publication of EA022348B1 publication Critical patent/EA022348B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение обеспечивает единичную дозу Ападеносона, фармакологического стресс-агента, и его применение в качестве фармакологического агента для визуализации миокардиальной перфузии.
EA201100132A 2008-07-03 2009-07-02 Единичная доза ападеносона EA022348B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7816908P 2008-07-03 2008-07-03
US15593709P 2009-02-27 2009-02-27
PCT/US2009/003939 WO2010002473A1 (en) 2008-07-03 2009-07-02 Unit dosage of apadenoson

Publications (2)

Publication Number Publication Date
EA201100132A1 true EA201100132A1 (ru) 2011-08-30
EA022348B1 EA022348B1 (ru) 2015-12-30

Family

ID=41152021

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100132A EA022348B1 (ru) 2008-07-03 2009-07-02 Единичная доза ападеносона

Country Status (24)

Country Link
US (6) US20100003193A1 (ru)
EP (1) EP2306971B1 (ru)
JP (2) JP2011526894A (ru)
KR (2) KR20140021726A (ru)
CN (1) CN102119023B (ru)
AU (1) AU2009266317B2 (ru)
BR (1) BRPI0913939A2 (ru)
CA (1) CA2729819C (ru)
CY (1) CY1116283T1 (ru)
DK (1) DK2306971T3 (ru)
EA (1) EA022348B1 (ru)
ES (1) ES2537069T3 (ru)
HK (1) HK1156250A1 (ru)
HR (1) HRP20150454T1 (ru)
IL (2) IL210428A (ru)
MX (1) MX2011000193A (ru)
MY (1) MY161655A (ru)
NZ (1) NZ590489A (ru)
PL (1) PL2306971T3 (ru)
PT (1) PT2306971E (ru)
SI (1) SI2306971T1 (ru)
SM (1) SMT201500123B (ru)
WO (1) WO2010002473A1 (ru)
ZA (1) ZA201100163B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002473A1 (en) 2008-07-03 2010-01-07 University Of Virginia Patent Foundation Unit dosage of apadenoson
CA2863685C (en) 2012-02-03 2020-10-13 Adenobio N.V. A method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits
CN109020881B (zh) * 2018-06-28 2020-04-28 新发药业有限公司 一种阿帕替尼的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
DE69120840T2 (de) * 1990-02-21 1996-11-21 Nz Government Supraleiter auf Thalliumbasis substituiert durch seltene Erden
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
NZ513096A (en) 1999-02-01 2003-01-31 Univ Virginia Compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
WO2002034966A1 (fr) * 2000-10-23 2002-05-02 National Institute Of Advanced Industrial Science And Technology Structure composite et procede et appareil destines a sa fabrication
US6620645B2 (en) * 2000-11-16 2003-09-16 G.T. Equipment Technologies, Inc Making and connecting bus bars on solar cells
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
JP4615221B2 (ja) * 2002-02-27 2011-01-19 フェリング ベスローテン フェンノートシャップ ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法
WO2003086408A1 (en) 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US6662088B1 (en) * 2002-06-28 2003-12-09 General Electric Company Methods and systems for inspecting aircraft fuselage frames
US7396825B2 (en) 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
CN101068825B (zh) 2004-08-02 2013-05-08 弗吉尼亚大学专利基金会 具有a2a激动剂活性的具有修饰的5＇-核糖基团的2-丙炔基腺苷类似物
DE602005011111D1 (de) 2005-06-03 2009-01-02 St Microelectronics Srl Selbstjustiertes Verfahren zur Herstellung von Phasenwechselspeicherzellen
US7767686B2 (en) 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
DE102006022450A1 (de) 2006-05-13 2007-11-15 Lanxess Deutschland Gmbh Wässrige Rußdispersionen für Ink-Jet
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
TW200905703A (en) * 2007-07-27 2009-02-01 Delta Electronics Inc Magnetic device and manufacturing method thereof
WO2010002473A1 (en) 2008-07-03 2010-01-07 University Of Virginia Patent Foundation Unit dosage of apadenoson

Also Published As

Publication number Publication date
PL2306971T3 (pl) 2015-07-31
DK2306971T3 (en) 2015-05-11
NZ590489A (en) 2013-01-25
KR20140021726A (ko) 2014-02-20
MY161655A (en) 2017-04-28
AU2009266317A1 (en) 2010-01-07
HK1156250A1 (en) 2012-06-08
US20170007722A1 (en) 2017-01-12
PT2306971E (pt) 2015-06-18
EA022348B1 (ru) 2015-12-30
IL210428A0 (en) 2011-03-31
CN102119023A (zh) 2011-07-06
KR20110028531A (ko) 2011-03-18
HRP20150454T1 (hr) 2015-06-19
SI2306971T1 (sl) 2015-07-31
IL245577B (en) 2019-05-30
JP2011526894A (ja) 2011-10-20
WO2010002473A1 (en) 2010-01-07
CA2729819A1 (en) 2010-01-07
US20140100185A1 (en) 2014-04-10
ES2537069T3 (es) 2015-06-02
IL245577A0 (en) 2016-06-30
US9415058B2 (en) 2016-08-16
AU2009266317B2 (en) 2013-12-05
US20130017153A1 (en) 2013-01-17
US20190022253A1 (en) 2019-01-24
US20170252463A1 (en) 2017-09-07
EP2306971B1 (en) 2015-02-25
EP2306971A1 (en) 2011-04-13
CA2729819C (en) 2014-08-26
MX2011000193A (es) 2011-03-24
CY1116283T1 (el) 2017-02-08
BRPI0913939A2 (pt) 2016-04-26
JP2013237702A (ja) 2013-11-28
ZA201100163B (en) 2011-09-28
CN102119023B (zh) 2014-04-09
SMT201500123B (it) 2015-09-07
IL210428A (en) 2016-05-31
US20100003193A1 (en) 2010-01-07
US9662406B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
CR11861A (es) Compuestos organicos
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201170227A1 (ru) Имидазолкарбоксамиды
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NO20074238L (no) Fiksert dosering av HER-antistoffer
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA201170441A1 (ru) Терапевтические противовирусные пептиды
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
CL2012000768A1 (es) Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales.
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
NI201000023A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
EA201000069A1 (ru) Новые гербициды
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CY1116283T1 (el) Δοσολογια μοναδας apadenoson

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU